WuXi XDC Cayman Inc. (HKG:2268)

Market Cap	69.21B +55.9%
Revenue (ttm)	6.61B +46.7%
Net Income	1.65B +38.4%
EPS	1.25 +34.9%
Shares Out	1.26B
PE Ratio	44.05
Forward PE	29.15
Dividend	n/a
Ex-Dividend Date	n/a

Volume	3,703,225
Open	54.35
Previous Close	54.90
Day's Range	53.30 - 56.70
52-Week Range	37.35 - 85.50
Beta	-0.75
Analysts	Strong Buy
Price Target	84.59 (+56.21%)
Earnings Date	Aug 18, 2026

About WuXi XDC Cayman

WuXi XDC Cayman Inc., an investment holding company, operates as a contract research, development, and manufacturing organization in China, North America, Europe, and internationally. It engages in the discovery, research, development, and manufacture of the drug substances and drug products of antibody drug conjugates, bioconjugates, monoclonal antibody intermediates, and payload-linkers associated with bioconjugates. It also provides international sales contracting services. Additionally, the company engages in the research and development, m...

• Industry: Diagnostics & Research
• Sector: Healthcare
• Founded: 2013
• Employees: 2,662
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 2268

Financial Performance

In 2025, WuXi XDC Cayman's revenue was 5.94 billion, an increase of 46.69% compared to the previous year's 4.05 billion. Earnings were 1.48 billion, an increase of 38.41%.

Financial numbers in CNY